Verastem Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Verastem has been growing earnings at an average annual rate of 9.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 43.4% per year.

Anahtar bilgiler

9.4%

Kazanç büyüme oranı

41.2%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı-43.4%
Özkaynak getirisi-223.7%
Net Marj-894.9%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

May 26

Verastem: Moving Forward

Sep 13

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Sep 01
Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Verastem Non-GAAP EPS of -$0.11 in-line

Aug 08

Verastem: Looking Increasingly Attractive

Jun 29

Verastem: Time To Take My Position Out Of Mothball

Apr 19

Vectoring In On Verastem

Jan 12

Verastem: Buying Opportunity Following Unjustified Sell-Off

Sep 22

Gelir ve Gider Dağılımı

Verastem nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:VSTM Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 2410-893772
31 Mar 240-1063467
31 Dec 230-873161
30 Sep 230-772850
30 Jun 230-752747
31 Mar 230-732649
31 Dec 223-742551
30 Sep 223-732551
30 Jun 223-782449
31 Mar 224-732444
31 Dec 212-712439
30 Sep 212-752638
30 Jun 2181-393840
31 Mar 2184-454739
31 Dec 2089-685941
30 Sep 2092-877543
30 Jun 2022-1308045
31 Mar 2021-1499346
31 Dec 1917-14910146
30 Sep 1915-12210442
30 Jun 1922-11310741
31 Mar 1928-899342
31 Dec 1827-727744
30 Sep 1826-795846
30 Jun 1810-813852
31 Mar 180-762649
31 Dec 170-682146
30 Sep 170-611942
30 Jun 170-461829
31 Mar 170-411824
31 Dec 160-361720
30 Sep 160-371721
30 Jun 160-441728
31 Mar 160-511734
31 Dec 150-581841
30 Sep 150-601843
30 Jun 150-581840
31 Mar 150-551838
31 Dec 140-531835
30 Sep 140-511734
30 Jun 140-481731
31 Mar 140-451629

Kaliteli Kazançlar: VSTM is currently unprofitable.

Büyüyen Kar Marjı: VSTM is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: VSTM is unprofitable, but has reduced losses over the past 5 years at a rate of 9.4% per year.

Büyüme Hızlandırma: Unable to compare VSTM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: VSTM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: VSTM has a negative Return on Equity (-223.67%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin